You searched for Solid tumor - GLOBAL (ex-US) / EN

A Phase 1 study of BGB-A3055 (anti-CCR8) with or without tislelizumab (anti-PD-1) in patients with solid tumors

Congress Resource

A Phase 1 study of BGB-A3055 (anti-CCR8) with or without tislelizumab (anti-PD-1) in patients with solid tumors

First-in-human study of BG-C9074 (B7-H4–targeting ADC) in advanced solid tumors: Dose escalation and safety expansion

Congress Resource

First-in-human study of BG-C9074 (B7-H4–targeting ADC) in advanced solid tumors: Dose escalation and safety expansion

A Phase 1 study of BGB-B2033 (GPC3 x 4-1BB bispecific antibody) monotherapy in patients with selected advanced or metastatic solid tumors: First disclosure of clinical data

Congress Resource

A Phase 1 study of BGB-B2033 (GPC3 x 4-1BB bispecific antibody) monotherapy in patients with selected advanced or metastatic solid tumors: First disclosure of clinical data

A phase 1 study of BGB-B2033 (GPC3 x 4-1BB bispecific antibody) monotherapy in patients with selected advanced or metastatic solid tumors: First disclosure of clinical data

Congress Presentation

A phase 1 study of BGB-B2033 (GPC3 x 4-1BB bispecific antibody) monotherapy in patients with selected advanced or metastatic solid tumors: First disclosure of clinical data

First-in-human study of BG-C9074 (B7-H4–targeting ADC) in advanced solid tumors: Dose escalation and safety expansion

Congress Presentation

First-in-human study of BG-C9074 (B7-H4–targeting ADC) in advanced solid tumors: Dose escalation and safety expansion

A phase 1 study of BGB-A3055 (anti-CCR8) with or without tislelizumab (anti-PD-1) in patients with solid tumors

Congress Presentation

A phase 1 study of BGB-A3055 (anti-CCR8) with or without tislelizumab (anti-PD-1) in patients with solid tumors

Pharmacodynamic (PD) characterization of BGB-24714, a second mitochondrial-derived activator of caspases (SMAC) mimetic, in a first-in-human study in solid tumors

Congress Resource

A phase 1 study of BGB-24714, a second mitochondrial-derived activator of caspases (SMAC) mimetic, as monotherapy or in combination with chemotherapy or concurrent chemoradiotherapy in solid tumors

Congress Resource

First-in-human, phase 1 study of BGB-26808 (hematopoietic progenitor kinase 1 [HPK1] inhibitor) ± tislelizumab (TIS; anti-PD-1) in advanced solid tumors (STs)

Congress Resource

A first-in-human, phase 1 study of BGB-15025 (hematopoietic progenitor kinase 1 [HPK1] inhibitor) as monotherapy and in combination (combo) with tislelizumab (TIS; anti-PD-1 antibody) in patients (pts) with advanced solid tumors (ST)

Congress Resource

Search Results

Taxonomy / Categories

Solid Tumors

Solid Tumors

Solid tumors

Solid tumors

Solid Tumors

A Phase 1 study of BGB-A3055 (anti-CCR8) with or without tislelizumab (anti-PD-1) in patients with solid tumors

First-in-human study of BG-C9074 (B7-H4–targeting ADC) in advanced solid tumors: Dose escalation and safety expansion

A Phase 1 study of BGB-B2033 (GPC3 x 4-1BB bispecific antibody) monotherapy in patients with selected advanced or metastatic solid tumors: First disclosure of clinical data

A phase 1 study of BGB-B2033 (GPC3 x 4-1BB bispecific antibody) monotherapy in patients with selected advanced or metastatic solid tumors: First disclosure of clinical data

First-in-human study of BG-C9074 (B7-H4–targeting ADC) in advanced solid tumors: Dose escalation and safety expansion

A phase 1 study of BGB-A3055 (anti-CCR8) with or without tislelizumab (anti-PD-1) in patients with solid tumors

Pharmacodynamic (PD) characterization of BGB-24714, a second mitochondrial-derived activator of caspases (SMAC) mimetic, in a first-in-human study in solid tumors

A phase 1 study of BGB-24714, a second mitochondrial-derived activator of caspases (SMAC) mimetic, as monotherapy or in combination with chemotherapy or concurrent chemoradiotherapy in solid tumors

First-in-human, phase 1 study of BGB-26808 (hematopoietic progenitor kinase 1 [HPK1] inhibitor) ± tislelizumab (TIS; anti-PD-1) in advanced solid tumors (STs)

A first-in-human, phase 1 study of BGB-15025 (hematopoietic progenitor kinase 1 [HPK1] inhibitor) as monotherapy and in combination (combo) with tislelizumab (TIS; anti-PD-1 antibody) in patients (pts) with advanced solid tumors (ST)

Welcome to BeOne Medical

Search Results

Taxonomy / Categories

Solid Tumors

Solid Tumors

Solid tumors

Solid tumors

Solid Tumors

A Phase 1 study of BGB-A3055 (anti-CCR8) with or without tislelizumab (anti-PD-1) in patients with solid tumors

First-in-human study of BG-C9074 (B7-H4–targeting ADC) in advanced solid tumors: Dose escalation and safety expansion

A Phase 1 study of BGB-B2033 (GPC3 x 4-1BB bispecific antibody) monotherapy in patients with selected advanced or metastatic solid tumors: First disclosure of clinical data

A phase 1 study of BGB-B2033 (GPC3 x 4-1BB bispecific antibody) monotherapy in patients with selected advanced or metastatic solid tumors: First disclosure of clinical data

First-in-human study of BG-C9074 (B7-H4–targeting ADC) in advanced solid tumors: Dose escalation and safety expansion

A phase 1 study of BGB-A3055 (anti-CCR8) with or without tislelizumab (anti-PD-1) in patients with solid tumors

Pharmacodynamic (PD) characterization of BGB-24714, a second mitochondrial-derived activator of caspases (SMAC) mimetic, in a first-in-human study in solid tumors

A phase 1 study of BGB-24714, a second mitochondrial-derived activator of caspases (SMAC) mimetic, as monotherapy or in combination with chemotherapy or concurrent chemoradiotherapy in solid tumors

First-in-human, phase 1 study of BGB-26808 (hematopoietic progenitor kinase 1 [HPK1] inhibitor) ± tislelizumab (TIS; anti-PD-1) in advanced solid tumors (STs)

A first-in-human, phase 1 study of BGB-15025 (hematopoietic progenitor kinase 1 [HPK1] inhibitor) as monotherapy and in combination (combo) with tislelizumab (TIS; anti-PD-1 antibody) in patients (pts) with advanced solid tumors (ST)

Welcome to BeOne Medical

You are now leaving the website